3-amino-6-(trifluoromethyl)picolinonitrile 、 硫酸 在
ice water 、 乙酸乙酯 、 Brine 作用下,
反应 3.0h,
以to get 6.8 g (89.47%) of off white solid的产率得到3-Amino-6-(trifluoromethyl)picolinamide
参考文献:
名称:
Piperidinyl derivatives as modulators of chemokine receptor activity
[EN] GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DU SOUS-TYPE 2 DE LA MÉLANOCORTINE (MC2R) À PIPÉRIDINE À DOUBLE SUBSTITUTION GEM ET LEURS UTILISATIONS
申请人:CRINETICS PHARMACEUTICALS INC
公开号:WO2021126693A1
公开(公告)日:2021-06-24
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
申请人:Carter Percy H.
公开号:US20070208056A1
公开(公告)日:2007-09-06
The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
[EN] PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] DERIVES DE PIPERIDINYL EN TANT QUE MODULATEURS DE L'ACTIVITE DU RECEPTEUR DE CHIMIOKINE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2007092681A2
公开(公告)日:2007-08-16
[EN] The present application describes substituted piperidinyl modulators of MIP-1 or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed. [FR] La présente invention concerne des modulateurs de pipéridinyl substitués de MIP-1 ou de CCR-1 ou des stéréoisomères ou sels dérivés pharmaceutiquement acceptables. Sont en outre révélés des procédés de traitement et de prévention de maladies inflammatoires telles que l'asthme et des maladies allergiques, ainsi que des pathologies autoimmunitaires telles que l'arthrite rhumatoïde et le rejet de transplant en utilisant lesdits modulateurs.